Drug Administration of Vietnam

Drug Administration of Vietnam
Name	Drug Administration of Vietnam
Native name	Cục Quản lý Dược Việt Nam
Formed	1995
Jurisdiction	Socialist Republic of Vietnam
Headquarters	Hanoi
Parent agency	Ministry of Health (Vietnam)
Chief1 name	Nguyễn Thanh Long
Chief1 position	Director

Drug Administration of Vietnam is the central regulatory body responsible for pharmaceutical oversight, licensing, quality control, and pharmacovigilance in the Socialist Republic of Vietnam. It operates within the administrative framework set by the Ministry of Health (Vietnam) and interacts with regional health departments, customs authorities, and international organizations. The administration's remit spans market authorization, Good Manufacturing Practice inspections, drug safety reporting, and coordination with law enforcement on controlled substances.

History and Legal Framework

The origins trace to regulatory reforms following the Doi Moi economic policies and the establishment of modern health institutions like the Ministry of Health (Vietnam), with statutory instruments enacted under the Law on Pharmacy (2005), subsequent amendments, and implementing decrees. Important legal milestones include decrees aligning domestic rules with the World Health Organization recommendations, circulars harmonizing standards with the ASEAN Pharmaceutical Product Working Group, and adoption of pharmacovigilance systems influenced by the International Conference on Harmonisation guidelines. Legislative interactions occurred alongside national public health campaigns linked to events such as the SARS outbreak and the COVID-19 pandemic (2019–present), prompting revisions to emergency authorization and import rules. The administration’s authority is shaped by linkage to ministries such as the Ministry of Public Security (Vietnam) for controlled substances, and coordination with agencies like the Drug Enforcement Administration in bilateral cooperation frameworks.

Organizational Structure and Agencies

The administration is nested within the Ministry of Health (Vietnam) and coordinates with provincial Departments of Health, the Vietnam Food Administration, the Vietnam Administration for Medical Devices and Health Insurance, and state-run pharmaceutical producers such as VNVC and national institutes like the National Institute of Hygiene and Epidemiology. Internal departments include divisions for drug registration, inspections, pharmacovigilance, and pricing, which liaise with the Health Insurance Fund and the National Institute of Drug Quality Control. The agency collaborates with academic partners including Hanoi Medical University, Ho Chi Minh City University of Medicine and Pharmacy, and research centers like the Institute of Tropical Medicine. Administrative oversight involves interaction with the Government Inspectorate (Vietnam) and budgetary reviews by the Ministry of Finance (Vietnam).

Drug Control Policies and Regulations

Regulatory policy covers market authorization, clinical trial approvals involving institutions such as Vinmec Research Institute of Stem Cell and Gene Technology, and contraindication guidance referencing international pharmacopoeias like the United States Pharmacopeia and the European Pharmacopoeia. Pricing and reimbursement decisions are coordinated with the Health Insurance Fund and shaped by directives from the Prime Minister of Vietnam. Controlled substance scheduling reflects convention commitments such as the Single Convention on Narcotic Drugs (1961), and regulatory action addresses counterfeit medicine through enforcement measures linked to the Customs Department (Vietnam). Pharmacovigilance reporting is structured in line with the World Health Organization's Uppsala Monitoring Centre standards, and post-marketing surveillance involves partnerships with hospitals like the 108 Military Central Hospital and the Cho Ray Hospital.

Enforcement and Anti-Narcotics Operations

Enforcement activities are conducted in cooperation with the Ministry of Public Security (Vietnam), the Vietnam Coast Guard, and customs authorities, often coordinated through taskforces established after high-profile seizures and operations against trafficking networks connected to the Golden Triangle. Major interdiction efforts have referenced international cooperation with agencies such as INTERPOL, the United States Drug Enforcement Administration, and the Australian Federal Police. Judicial processes involve the Supreme People's Court of Vietnam and prosecutorial action by the Supreme People's Procuracy of Vietnam under statutes criminalizing illegal distribution and manufacturing. High-profile cases have involved cross-border investigations with neighboring states including China, Laos, and Cambodia.

Public Health and Harm Reduction Programs

Public health initiatives incorporate harm reduction strategies implemented in coordination with non-governmental organizations like Médecins Sans Frontières and international partners including the United Nations Office on Drugs and Crime and the World Health Organization. Programs address opioid substitution therapy, needle-exchange pilot projects, and community-based rehabilitation linked to provincial health services and social support through entities such as the Vietnam Chamber of Commerce and Industry-backed CSR initiatives. Health education campaigns have been run with media outlets and institutions such as Vietnam Television and universities to reduce misuse and promote rational drug use in clinics including Bach Mai Hospital and community pharmacies regulated under national licensing schemes.

International Cooperation and Treaties

The administration engages multilaterally through ASEAN frameworks, participates in harmonization via the ASEAN Pharmaceutical Product Working Group, and signs bilateral memoranda with counterparts like the Food and Drug Administration (United States), the European Medicines Agency, and regulatory agencies in Japan and South Korea. It implements treaty obligations under the Single Convention on Narcotic Drugs (1961), the Convention on Psychotropic Substances (1971), and collaborates on technical assistance from the World Health Organization and the United Nations Office on Drugs and Crime. Multinational research and regulatory convergence projects have involved partners such as GlaxoSmithKline, Pfizer, Novartis, academic consortia including Johns Hopkins Bloomberg School of Public Health, and regional bodies like the Asia-Pacific Economic Cooperation forum.

Category:Pharmaceutical regulatory agencies Category:Health in Vietnam